$IMUC News

Last published 4y ago

4y agoIMUCEOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger AgreementPR NewswireMONTVALE, N.J. and LOS ANGELES, Dec. 2, 2021 /PRNewswire/ -- EOM Pharmaceuticals, Inc. ("EOM"), a privately held, clinical-stage pharmaceutical company, and ImmunoCellular Therapeutics, Ltd. (OTC:IMUC) ("ImmunoCellular") today announced that the compani
5y agoIMUCImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) MarketPR NewswireLOS ANGELES, June 28, 2021 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC:IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will
12y agoIMUCImmunoCellular Therapeutics Announces First Patient Receives Vaccine in Phase I Trial of Cancer Vaccine ICT-121 in Recurrent GlioblastomaBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today that the first patient in the phase I clinical trial of ICT-121, a cancer vaccine targeting recurrent glioblastoma multiforme (GBM, or brain cancer), has received the vaccine. ICT-121 is a dendritic cell vaccine targeting CD-133, an important cancer stem cell marker that is commonly ...
12y agoIMUCImmunoCellular Therapeutics Phase II Study Demonstrates That Glioblastoma Patients Live Longer Without Disease Progression When Treated With ICT-107Business WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT:IMUC) announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial. A comparison of PFS between ICT-107 and p ...
12y agoIMUC NBSImmunoCellular Therapeutics Expands Manufacturing Relationship with Progenitor Cell Therapy, LLC for Dendritic Cell VaccinesBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT:IMUC) announced the expansion of its relationship with Progenitor Cell Therapy, LLC (“PCT”), a subsidiary of NeoStem, Inc. (NASDAQ:NBS), for current good manufacturing practices (cGMP) services for ImmunoCellular’s dendritic cell-based vaccines. PCT currently manufactures ICT-121, a dendritic cell vaccine ...
13y agoIMUCImmunoCellular Therapeutics Announces Third Quarter 2013 Financial ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced financial results for the quarter ended September 30, 2013.
13y agoIMUCImmunoCellular Therapeutics to Report Financial Results for the Third Quarter, 2013 on November 6thBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that it plans to report third quarter, 2013 financial results on Wednesday, November 6, 2013. ImmunoCellular will host a conference call and webcast to discuss financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, President ...
13y agoIMUCImmunoCellular Therapeutics to Participate in Webcast Discussion of Immunotherapy and Brain Cancer on September 23rdBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer, and John Yu, MD, Founder and Chief Scientific Officer of ImmunoCellular, will participate in a webcast, titled “Glioblastoma – Brain Cancer: The Next Generation of Therapies,” being sponsored by ProActive Capital Group on Monday, September ...
13y agoIMUCImmunoCellular Therapeutics to Present at BioCentury NewsMakers Conference on September 27thBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that John Yu, MD, Founder and Chief Scientific Officer of ImmunoCellular, will present a corporate overview and business update at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 27, 2013 at 2:30 p.m. ET at the Millennium Broadway Hotel in New York C ...
13y agoIMUCImmunoCellular Therapeutics Appoints Anthony J. Gringeri, PhD, as Senior Vice President, Strategic ResourcesBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Anthony J. Gringeri, PhD, has been appointed Senior Vice President, Strategic Resources, reporting to Andrew Gengos, Chief Executive Officer. In this newly created leadership position, Dr. Gringeri will bring his wide range of expertise to bear on key functions, including projec ...
13y agoIMUCFaruqi & Faruqi, LLP Launches an Investigation against ImmunoCellular Therapeutics, Ltd. (IMUC) for Potential Breaches of Fiduciary Duties by Its Board of DirectorsBusiness WireNEW YORK--(BUSINESS WIRE)--Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for an amen ...
13y agoIMUCImmunoCellular Therapeutics Announces Second Quarter 2013 Financial ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced financial results for the quarter ended June 30, 2013.
13y agoIMUCImmunoCellular Therapeutics to Report Financial Results for the Second Quarter, 2013 on August 7thBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that it plans to report second quarter, 2013 financial results on Wednesday, August 7, 2013. ImmunoCellular will host a conference call and webcast to discuss financial results and provide a business update at 5:00 p.m. ET that day. The call will be hosted by Andrew Gengos, President ...
13y agoIMUCImmunoCellular Therapeutics Announces Initiation of Phase I Trial of Cancer Vaccine ICT-121 in Recurrent GlioblastomaBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced initiation of a phase I clinical trial of cancer vaccine ICT-121 as a potential treatment for patients with recurrent glioblastoma multiforme (GBM). The investigator-sponsored phase I trial is being conducted at Cedars-Sinai Medical Center in Los Angeles, CA, by Jeremy Rudnick, MD, a ...
13y agoIMUCImmunoCellular Therapeutics Announces Recommendation of Data Monitoring Committee to Continue ICT-107 Phase II Trial Following Interim AnalysisBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the Data Monitoring Committee (DMC) has completed a pre-specified interim analysis of the ICT-107 phase II clinical trial in patients with newly diagnosed glioblastoma and recommended that the company continue the trial to completion.
13y agoIMUCImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on May 30thBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the Marcum MicroCap Conference on Thursday, May 30, 2013 at 9:00 am ET at the Grand Hyatt hotel, New York, New York.
13y agoIMUCImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Cancer Vaccine TargetBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a patent covering methods of use of interleukin 13-receptor alpha 2 protein (IL-13Rα2) in cancer immunotherapy. IL-13 is an immune regulatory cytokine and IL-13Rα2 is highly and specifically expressed in glioblastoma, ovarian and o ...
13y agoIMUCImmunoCellular Therapeutics Announces First Quarter 2013 Financial ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced financial results for the quarter ended March 31, 2013.
13y agoIMUCImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2013 May 9, 2013Business WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that it plans to report first quarter 2013 financial results on Thursday, May 9, 2013. ImmunoCellular will host a conference call and webcast to discuss financial results and provide a business update at 5:00 p.m. ET that day. The call will be hosted by Andrew Gengos, President and C ...
13y agoIMUCImmunoCellular Therapeutics to Present at Future Leaders Conference on April 5thBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the BioCentury and Thomson Reuters 20th Annual Future Leaders in the Biotech Industry conference on Friday, April 5, 2013 at 11:00 am ET at the Millennium Broadway ...
13y agoIMUCImmunoCellular Therapeutics to Present at ROTH Conference on March 18thBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 25th Annual ROTH Conference on Monday, March 18, 2013 at 1:30 pm PT at the Ritz-Carlton, Laguna Niguel, CA.
13y agoIMUCImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2012 Financial ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced financial results for the year and quarter ended December 31, 2012.
13y agoIMUCImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer VaccineBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a key patent application covering ICT-121, an immunotherapeutic vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors. The patent includes claims covering comp ...
13y agoIMUCImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2012 on March 5, 2013Business WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2012 financial results on Tuesday, March 5, 2013. ImmunoCellular will host a conference call and webcast to discuss financial results and provide a business update at 5:00 pm ET that day. The call will be hosted by Andrew Gengos, P ...
13y agoIMUCImmunoCellular Therapeutics to Present at BIO CEO & Investor Conference on February 11thBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 15th Annual BIO CEO & Investor Conference on Monday, February 11, 2013 at 10:00 am ET at the Waldorf Astoria Hotel in New York City.
13y agoIMUCImmunoCellular Therapeutics’ Investigational New Drug (IND) Application for ICT-140 Allowed by the FDABusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial. ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer s ...
13y agoIMUCImmunoCellular Therapeutics Provides Update on Corporate MilestonesBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today provided an update on current and anticipated corporate milestones.
13y agoIMUCImmunoCellular Therapeutics Appoints Gary S. Titus to its Board of DirectorsBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced the appointment of Gary S. Titus to its board of directors. Mr. Titus is currently the Senior Vice President and Chief Financial Officer of SciClone Pharmaceuticals, Inc. and has more than 20 years of business experience in the healthcare and biopharmaceutical industries. Mr. Titus h ...
13y agoIMUCImmunoCellular Therapeutics Appoints Andrew Gengos as Chief Executive OfficerBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today the appointment of Andrew Gengos as President and Chief Executive Officer and member of the Board of Directors. With more than 20 years in the life science industry, Mr. Gengos’ experience includes executive leadership positions in both large and emerging companies, with broad expert ...
14y agoIMUCImmunoCellular Therapeutics Reports Third Quarter 2012 Financial ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced third quarter results for the period ended September 30, 2012.
14y agoIMUCImmunoCellular Therapeutics to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14thBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that John S. Yu, MD, Interim Chief Executive Officer, will present a corporate overview and business update at the Lazard Capital Markets 9th Annual Healthcare Conference on November 14, 2012 at 11:00 am ET at the Pierre Hotel in New York City.
14y agoIMUCImmunoCellular Therapeutics Provides an Update on Recent 2012 Achievements and Anticipated MilestonesBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) provided an update on recent 2012 achievements and anticipated milestones following the closing of its follow-on financing.
14y agoIMUCImmunoCellular Therapeutics, Ltd. Announces Pricing of its Previously Announced Public Offering of Common Stock and WarrantsBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that it has priced an underwritten public offering of an aggregate of 10,000,000 shares of its Common Stock, at a price to the public of $2.10 per share, and warrants to purchase up to an aggregate of 4,500,000 shares of Common Stock. The net offering proceeds to ImmunoCellular from ...
14y agoIMUCImmunoCellular Therapeutics, Ltd. Announces Proposed Public Offering of Common Stock and WarrantsBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) today announced that it intends to offer shares of its common stock and warrants in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock and warrants to cover over-allotments, if any. Lazard Capital Markets LLC is acting as so ...
14y agoIMUCImmunoCellular Therapeutics to Present at 3rd Annual Cancer Immunotherapy Conference and 2012 BIO Investor ForumBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that Peter Ho, PhD, Director of Business Development, will present a company overview at 2:00 pm ET and participate in a panel discussion on advances in immunotherapy for glioma at 2:45 pm ET at the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference on Thursday, Octob ...
14y agoIMUCImmunoCellular Therapeutics Completes Enrollment of Phase II Trial of ICT-107 in GlioblastomaBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today that the company has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma. A total of 278 patients at 25 participating sites have been enrolled in this ...
14y agoIMUCImmunoCellular Therapeutics to Present at Two September 2012 Investor ConferencesBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that John S. Yu, MD, Interim Chief Executive Officer, will present a corporate overview and business update at the BioCentury and Thomson Reuters Newsmakers in the Biotech Industry Conference on September 7, 2012 at 11:30 am ET at the Millennium Broadway Hotel in New York City, and a ...
14y agoIMUCImmunoCellular Therapeutics Appoints John S. Yu, MD, as Interim Chief Executive OfficerBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced today that the Board of Directors has appointed John S. Yu, MD, as Interim Chief Executive Officer and President, and has accepted the resignation of Manish Singh, PhD, effective immediately, from the CEO, President, and Board positions. Dr. Yu will continue to serve as Chief Scientific Of ...
14y agoIMUCImmunoCellular Therapeutics Reports Second Quarter ResultsBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) (“ImmunoCellular” or the “Company”), today announced second quarter results for the period ended June 30, 2012.
14y agoIMUCImmunoCellular Therapeutics’ ICT-107 featured on CNN’s Sanjay Gupta MDBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (NYSE MKT: IMUC) a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it was featured on CNN’s Sanjay Gupta MD last weekend. The show profiled IMUC’s dendritic cell-based vaccine, ICT-07, which is currently undergoing a Phase IIb clinical trial treating newly di ...
14y agoIMUCImmunoCellular Therapeutics’ Data From Phase I Trial of ICT-107 Accepted for Publication in Prestigious Medical Journal, Cancer Immunology, ImmunotherapyBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (NYSE MKT: IMUC) announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy (http://www.springerlink.com/content/n0018574g9m4v587/fulltext.pdf). In the publication, the data showed that the expre ...
14y agoIMUCImmunoCellular Therapeutics Announces Clearance of IND Application for Phase I Study of Company’s Second Vaccine Product Candidate in Recurrent GBMBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (NYSE MKT: IMUC) today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC’s novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
14y agoIMUCImmunoCellular Therapeutics To Ring Opening Bell At The New York Stock ExchangeBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular Therapeutics”, “ImmunoCellular”, or the Company”) (NYSE MKT: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that it is scheduled to ring The Opening Bell at the New York Stock Exchange (NYSE) on Thursday, July 19th ,2012 to commemorate the Company’s re ...
14y agoIMUCImmunoCellular Therapeutics’ Brain Cancer Technology Receives Important Japanese Patent AllowanceBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular Therapeutics” or the Company”) (NYSE MKT: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license. The patent cov ...
14y agoIMUCImmunoCellular Provides Update on Phase II Clinical Trial of ICT-107 for Treatment of GlioblastomaBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC), a clinical stage biotechnology company that is focused on developing new immune-based products to treat cancer, announced today that it will expand its current Phase IIb trial of ICT-107 from 102 to up to 123 patients with glioblastoma multiforme (GBM) and who are HLA-A1/A2 positiv ...
14y agoIMUCImmunoCellular to Present at 2012 BIO International ConventionBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC), a clinical stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer, announced today that Manish Singh, PhD, President and Chief Executive Officer of the Company will be presenting at the 2012 BIO International Convention bein ...
14y agoIMUCImmunoCellular Therapeutics Set to be Added to Russell 3000, Russell Global and Russell Microcap IndexesBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”)(NYSE MKT: IMUC), a clinical stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer, today announced that it is scheduled to join the U.S. broad-market Russell 3000®, Global and Microcap Indexes when Russell Investments reconstitutes its compr ...
14y agoIMUCImmunoCellular Therapeutics to Present Long-term Survival Data from Clinical Study of ICT-107 in Glioblastoma Multiforme at American Society of Clinical Oncology MeetingBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC), announced today it will present new data from the previously completed Phase I clinical trial of ICT-107, the Company’s lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. The abstract, titled ...